ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,121 to 3,140 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Alirocumab 150 mg Q2W vs Placebo Q2W: serious adverse events290 of 1,550

154 of 788

-0.8 points

-4.3 to 2.5

2,338NCT01507831

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections vs Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections: Number of Participants With Virologically Confirmed Cases of ZIKV (Part B Only)1 of 1,170

2 of 1,168

-0.1 points

-0.5 to 0.3

2,338NCT03110770

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections vs Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections: Number of Participants With Subclinical Cases of ZIKV (Part B Only)1 of 1,170

0 of 1,168

0.1 points

-0.2 to 0.5

2,338NCT03110770

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography209 of 1,157

220 of 1,178

-0.6 points

-3.8 to 2.5

2,335NCT02173379

Absorb IV Randomized Controlled Trial

TDF/FTC vs Placebo: Incidence of Confirmed Syphilis During Follow-Up147 of 1,155

132 of 1,171

1.5 points

-1.2 to 4.1

2,326NCT00458393

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

Folic Acid 4 mg vs Placebo: Preterm Birth297 of 1,150

304 of 1,164

-0.3 points

-3.9 to 3.3

2,314NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Incentives vs Usual Care: deaths from any cause104 of 1,114

125 of 1,200

-1.1 points

-3.5 to 1.4

2,314NCT02969915

Strategies to Improve the HIV Care Continuum Among Key Populations in India

Incentives vs Usual Care: serious adverse events104 of 1,114

125 of 1,200

-1.1 points

-3.5 to 1.4

2,314NCT02969915

Strategies to Improve the HIV Care Continuum Among Key Populations in India

Fosaprepitant vs Aprepitant: serious adverse events148 of 1,143

157 of 1,169

-0.5 points

-3.2 to 2.3

2,312NCT00619359

Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

Cervarix Group vs Placebo Group: Number of Subjects With Unsolicited Adverse Events for Subjects Seropositive and/or DNA Positive for Either HPV-16 or HPV-18 at Baseline295 of 1,131

307 of 1,179

0.0 points

-3.5 to 3.6

2,310NCT00779766

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

Cervarix Group vs Placebo Group: Number of Subjects With Medically Significant Conditions Regardless of Causal Relationship to Vaccination and Intensity for Subjects Seropositive and/or DNA Positive for Either HPV-16 or HPV-18 at Baseline64 of 1,131

75 of 1,179

-0.7 points

-2.7 to 1.3

2,310NCT00779766

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

Aspirin vs Warfarin: serious adverse events617 of 1,163

632 of 1,142

-2.3 points

-6.3 to 1.8

2,305NCT00041938

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial

Q/LAIV (MEDI3250) vs All FluMist Group: serious adverse events6 of 1,382

5 of 923

-0.1 points

-0.9 to 0.5

2,305NCT01091246

A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children

Wearable Defibrillator vs Conventional Treatment: Sudden Death Mortality25 of 1,524

19 of 778

-0.8 points

-2.2 to 0.4

2,302NCT01446965

Vest Prevention of Early Sudden Death Trial and VEST Registry

Wearable Defibrillator vs Conventional Treatment: All Cause Mortality48 of 1,524

38 of 778

-1.7 points

-3.6 to -0.1

2,302NCT01446965

Vest Prevention of Early Sudden Death Trial and VEST Registry

Wearable Defibrillator vs Conventional Treatment: deaths from any cause48 of 1,524

38 of 778

-1.7 points

-3.6 to -0.1

2,302NCT01446965

Vest Prevention of Early Sudden Death Trial and VEST Registry

Wearable Defibrillator vs Conventional Treatment: serious adverse events475 of 1,524

253 of 778

-1.4 points

-5.4 to 2.6

2,302NCT01446965

Vest Prevention of Early Sudden Death Trial and VEST Registry

Transdisciplinary Approach vs Multidisciplinary Approach: Behavioral Symptoms104 of 648

299 of 1,654

-2.0 points

-5.3 to 1.5

2,302NCT03442322

Optimizing Care for Patients With Dementia

Folic Acid 4 mg vs Placebo: Preeclampsia169 of 1,144

156 of 1,157

1.3 points

-1.6 to 4.1

2,301NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Transdisciplinary Approach vs Multidisciplinary Approach: Rejection of Care75 of 648

282 of 1,653

-5.5 points

-8.4 to -2.3

2,301NCT03442322

Optimizing Care for Patients With Dementia

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=157"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=157

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01507831-sae",
        "title": "Alirocumab 150 mg Q2W vs Placebo Q2W: serious adverse events",
        "summary": "290 of 1550 against 154 of 788; risk difference -0.8 points, 95% interval -4.3 to 2.5; NCT01507831, Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)",
        "record": "/library/comparisons/NCT01507831-sae",
        "nct_id": "NCT01507831",
        "kind": "serious-adverse-events",
        "participants": 2338,
        "risk_difference": {
          "value": -0.008334697887669884,
          "lower": -0.042919187632066036,
          "upper": 0.024720830762770235
        },
        "group_1": "290 of 1,550",
        "group_2": "154 of 788",
        "difference": "-0.8 points",
        "interval": "-4.3 to 2.5",
        "trial_title": "Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)"
      },
      {
        "id": "NCT03110770-5dff3b50",
        "title": "Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections vs Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections: Number of Participants With Virologically Confirmed Cases of ZIKV (Part B Only)",
        "summary": "1 of 1170 against 2 of 1168; risk difference -0.1 points, 95% interval -0.5 to 0.3; NCT03110770, VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents",
        "record": "/library/comparisons/NCT03110770-5dff3b50",
        "nct_id": "NCT03110770",
        "kind": "outcome",
        "participants": 2338,
        "risk_difference": {
          "value": -0.0008576279124224329,
          "lower": -0.005421752703196649,
          "upper": 0.003303034155876399
        },
        "group_1": "1 of 1,170",
        "group_2": "2 of 1,168",
        "difference": "-0.1 points",
        "interval": "-0.5 to 0.3",
        "trial_title": "VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=158",
  "request_id": "QOpjtUAoGCoO_X0_"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?